Work

MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer

Year: 2022

Type: article

Abstract: Immune checkpoint inhibitors (ICIs) represent a new paradigm in cancer immunotherapy, but can be largely restricted by the limited presence of CD8 + cytotoxic T lymphocytes (CTLs) in colorectal cancer (CRC) patients with microsatellite stable (MSS) tumors. Here, through next-generation sequencing, we identify microtubule-associated protein 7 domain 2 (MAP7D2) as an exploitable therapeutic maneuver to improve the efficacy of ICIs for MSS CRC therapy. In human CRC tissues, MAP7D2 expression is significantly increased in MSS CRC, and MAP7D2 adversely correlates with the presence of antitumor T lymphocytes. In vitro and in viv o experiments demonstrate that MAP7D2 knockdown significantly increases the infiltration of CD8 + CTLs, thereby inhibiting tumor progression and improving the efficacy of ICIs in MSS CRC murine models. Mechanistically, MAP7D2 interacts with MYH9 and protects it from ubiquitin-mediated degradation, subsequently decreasing the secretion of HMGB1, which suppresses the infiltration of CD8 + CTLs in MSS CRC. These findings highlight the importance of MAP7D2 in determining the infiltration of CD8 + CTLs and indicate that targeting MAP7D2 in MSS CRC may present a novel antitumor immunotherapy.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2022.09.001